Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06632873
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-07
Brief Title:
177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Therapeutic Efficiency and Response to 177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Researchers has conducted extensive research on the treatment of neuroendocrine tumors with 177Lu-EB-TATE and the treatment of FAP-expressing tumors with 177Lu-EB-FAPI and some researches have revealed 68Ga-TATE-RGD in imaging studies of neuroendocrine tumors to find that the dual-targeted tracer showed an increasing TBR suggesting the tracer kinetic advantage of TATE-RGD compared to the single-target tracer DOTATATE the dual-target TATE-RGD probe has a clear advantage in detecting liver metastases of NETs and it can be explored for potential therapeutic uses of TATE-RGD in future studies and used for related companion diagnostics in targeted radioisotope therapy RLT
Detailed Description:
Integrin αvβ3 is highly expressed in certain tumor cells and newly formed blood vessels making it an ideal target for diagnosis and treatment of integrin αVβ3 positive tumors 177Lu-TATE-RGD is a novel drug developed independently in China providing an effective target for the treatment of integrin αVβ3 positive tumors All patients underwent whole-body 68Ga-TATE-RGD PETCT screening within one week and received a single intravenous injection of 148-333 GBq 40-100 mCi 177Lu-TATE-RGD within one week Blood samples were collected from the vein in 1-2 mL volumes at 5 minutes 3 hours 24 hours 72 hours and 168 hours after injection to measure radioactivity Then whole-body planar and SPECTCT imaging was performed at 3 24 48 72 96 120 and 168 hours after the injection of 177Lu-TATE-RGD The in vivo radiation dose of 177Lu-TATE-RGD was analyzed and calculated and the therapeutic effect and response were evaluated
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None